AngioDynamics (ANGO) Releases Earnings Results, Beats Expectations By $0.03 EPS

AngioDynamics (ANGO) reported quarterly earnings results on Wednesday, Jul-13-2016. The company said it had a profit of $0.19 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.03. Analysts had a consensus of $0.16. The company posted revenue of $93.40 million in the period, compared to analysts expectations of $88.64 million. The company’s revenue was up 2.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.14 EPS.

AngioDynamics closed down -0.02 points or -0.14% at $14.48 with 2,78,896 shares getting traded on Monday. Post opening the session at $14.63, the shares hit an intraday low of $14.45 and an intraday high of $14.73 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

In a different news, on May 9, 2016, Charles R Greiner (VP – Global Franchise) sold 3,508 shares at $12.31 per share price. According to the SEC, on Apr 25, 2016, Stephen A Trowbridge (SVP and General Counsel) sold 12,940 shares at $12.26 per share price. On Feb 19, 2015, Stark Richard (SVP, GM – Oncology) sold 18,100 shares at $18.53 per share price, according to the Form-4 filing with the securities and exchange commission.

AngioDynamics Inc. designs manufactures and sells a range of medical surgical and diagnostic devices used by professional healthcare providers for vascular access for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive image-guided procedures. The Company offers products within three product groupings: Peripheral Vascular Vascular Access and Oncology/Surgery. The Company’s Peripheral Vascular products include fluid management venous thrombus management as well as other core products. The Company’s BioFlo products incorporate Endexo technology into the manufacturing and design of its Vascular Access products. Its Oncology/Surgery product offerings include its microwave ablation products its radiofrequency ablation (RFA) and its NanoKnife product lines.


Leave a Reply

AngioDynamics - Is it time to Sell?

Top Brokerage Firms are advising their investors on AngioDynamics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.